Methods and compositions for regulating activity of a poxvirus viral polymerase by modulating the assembly and/or interaction of one or more subunits of the viral polymerase are described.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

The present invention relates, in part, to methods of generating immune responses in subjects to treat an infectious disease.

The present invention relates, in part, to methods of generating immune responses in subjects to treat an infectious disease.

Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

A method of protecting a respiratory tract or a lung from damage is provided. The method comprises administering a pharmaceutical composition to a patient in need thereof. The pharmaceutical composition comprises trehalose or a trehalose derivative.

The present invention relates to a metal (hydr)oxide composite comprising a poorly soluble drug, a method for manufacturing same, and a pharmaceutical composition comprising same.

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

By a Selective Elimination of Host Cells Capable of Producing HIV (SECH) approach, which includes a combination of latency reversal, blocking of new infections, inhibition of autophagy and induction of apoptosis, host cells harboring productive HIV infections can be cleared from a subject. Disclosed herein are methods for treating or inhibiting HIV in a subject, comprising a) reactivating latent HIV integrated into the genome of a cell infected with HIV in the subject, b) optionally administering to the subject an effective amount of a therapeutic agent to inhibit HIV infection, and c) administering to the subject an effective amount of a therapeutic agent to eliminate or reduce the number of cells containing replication-competent HIV. Kits for treating or inhibiting HIV in a subject are also disclosed.